NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022
Margaret von Mehren, John M. Kane, Richard F. Riedel, Jason K. Sicklick, Seth M. Pollack, Mark Agulnik, Marilyn M. Bui, Janai R. Carr, Edwin Choy, Mary Connelly, Sarah Dry, Kristen N. Ganjoo, Ricardo González, Ashley M. Holder, Jade Homsi, Vicki L. Keedy, Ciara M. Kelly, Edward Kim, David A. Liebner, Martin D. McCarter, Sean V. McGarry, Nathan W. Mesko, Christian F. Meyer, Alberto S. Pappo, Amanda Parkes, Ivy A. Petersen, Matthew M. Poppe, Scott M. Schuetze, Jacob E. Shabason, Matthew B. Spraker, Melissa N. Zimel, Mary Anne Bergman, Hema Sundar, Lisa E. Hang
Abstract
Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.